

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA - Durvalumab with platinum-based chemotherapy for untreated advanced or recurrent endometrial cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Final draft guidance

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No additional potential equality issues were raised at consultation.  
Consultees reiterated the following points:

- Incidence rates and mortality for endometrial cancer are higher in the Black ethnic group compared with White ethnic group.
- Incidence of different molecular subtypes of endometrial cancer (including MMR status) varies across ethnic groups. People in Black ethnic groups may also have more aggressive histology and may be more likely to have molecular subtypes with a poorer prognosis.

Race is a protected characteristic under the Equality Act 2010. The committee considered whether or not a negative recommendation in the pMMR subgroup could indirectly discriminate against people in Black ethnic groups. The committee considered that this would be a proportionate means of achieving the legitimate aim of maximising public health. This is because durvalumab plus platinum-based chemotherapy, followed by durvalumab plus olaparib, was not cost effective in the pMMR population.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups?

|   |
|---|
| If so, what are the barriers to, or difficulties with, access for the specific group? |
| N/A   |

|   |
|---|
| 3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
| N/A   |

|  |
|--|
| 4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality? |
| N/A  |

|  |
|--|
| 5. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where? |
| Yes, section 3.17.   |

**Approved by Associate Director: Emily Crowe .....**

**Date:** 22/05/2025